Quest Diagnostics account plan
Extensive clinical diagnostic testing
At a glance
Quest Diagnostics is a US clinical laboratory company with 2025 net revenues of $11,035 million and nearly 57,000 employees.
Quest Diagnostics provides diagnostic testing in the United States, serving about one-third of US adults and about half of US physicians and hospitals each year through ~2,400 patient service centers; it also operates LifeLabs in Canada. 2025 net revenues were $11,035 million (+11.8%; organic growth 5.3%), with operating income of $1,556 million and net income attributable to Quest of $992 million. It processed ~244 million test requisitions in 2025 and has nearly 57,000 employees. Its customers are physicians, hospitals, payers, life insurers and consumers.
Business units
Diagnostic Information Services (DIS)
97.7% of 2025 revenue ($10,785 million)Clinical lab testing for physicians, hospitals and consumers, including Advanced Diagnostics (over $1 billion on double-digit growth), hospital reference testing and Collaborative Lab Solutions. Q3 2026 DIS revenues were $3,035 million (+10.2%).
Diagnostic Solutions (DS)
2.3% of 2025 revenue ($250 million)ExamOne risk assessment for life insurers and healthcare IT such as Quanum. Q3 2026 revenues were $62 million.
Strategic priorities
- Growth across physician, hospital and consumer channels
- High single-digit growth in physicians, double-digit growth in hospitals in Q3 2026, and consumer health growth expected to exceed 30% for the year.
- Collaborative Lab Solutions with health systems
- Co-Lab Solutions across all 21 Corewell Health hospitals; Co-Lab Solutions is expected to generate about $1 billion of revenue in 2026.
- Outreach and lab acquisitions
- M&A targets 1-2% revenue growth a year, including an agreement to acquire outreach lab assets from a Northeastern US health system.
- Consumer channel
- QuestHealth.com is a $100 million run-rate business; an Apple Health app panel of over 50 biomarkers launches around year-end, with partners including WHOOP, Oura and Function Health.
- Cost savings through Invigorate, automation and AI
- Invigorate targets 3% annual cost savings; automated aliquoting runs in 10 labs and AI collaboration is under way with Google Cloud.
Latest results
In Q3 2026 net revenues were $3,097 million (+10.0%), with DIS organic growth of 10.1% and volume up 14.5%, of which 9.5% came from the Corewell Health relationship and Fresenius dialysis testing. Revenue per requisition fell 4.2% because of that routine-testing mix. Reported diluted EPS was $2.78 and adjusted diluted EPS $3.00 (+15.4%). Full-year 2026 guidance was raised to revenues of $12.065-12.105 billion and adjusted EPS of $11.25-11.35, with capex of about $550 million.
Investments and deals
- Corewell Health joint venture
- 51/49 lab JV in Michigan closed in January 2026; a new Michigan lab is due to be operational during 2027.
- Project Nova
- Epic-based modernization of Order to Cash running to 2031-2032; it moved to build phase with the first Epic lab deployment in fall 2027.
- Lab asset acquisitions
- Spectra Laboratories assets bought from Fresenius for $84 million; LifeLabs acquired in 2024.
- Capex and shareholder returns
- Capex was $527 million in 2025 and is guided at about $550 million for 2026; an additional $1 billion buyback was authorized and the dividend raised 7.5% to $0.86 per quarter.
Challenges and risks
- PAMA Medicare fee cuts
- The 2027 impact is estimated at about 1% of total revenues; Quest lobbies for the RESULTS Act.
- Payer and policy pressure
- Payer utilization controls, OBBBA and expiry of ACA tax credits could cost up to 50-60 bp of revenue by 2028.
- Cybersecurity
- A cybersecurity incident on a test-ordering system was disclosed on October 22, 2026.
- Pricing mix and competition
- Unit price is generally flat, and Quest competes with hospital labs and Laboratory Corporation of America; labor supply is a stated risk.
What leadership says
“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI.”
“We expect co-lab solutions to generate approximately $1 billion in annual revenues in 2026.”
“further advanced our position as the premier lab engine powering the wellness industry”
Where a supplier can help
- Lab automation and AI
- The Invigorate 3% savings target and automation and AI in labs open doors for lab robotics, AI imaging and workflow vendors.
- Epic migration support
- Project Nova's Epic-based Order to Cash modernization needs implementation, data migration and testing partners through 2031-2032.
- Security of ordering systems
- The cybersecurity incident on a test-ordering system makes security assessment and monitoring services relevant.
- Consumer and digital health partnerships
- The consumer channel and the Apple Health app panel call for digital marketing, ecommerce and wearables integration partners.
- Health system lab outsourcing
- Co-Lab Solutions and the new Michigan lab create needs for lab construction, equipment and logistics suppliers.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Quest Diagnostics?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal year 2025
- Quest Diagnostics is the US clinical lab leader: 2025 net revenues of $11,035 million (+11.8%; organic growth 5.3%), operating income $1,556 million, net income attributable to Quest $992 million, diluted EPS $8.75, operating cash flow $1,886 million, capex $527 million.
- Two businesses: Diagnostic Information Services (DIS, $10,785 million, 97.7% of revenue, the only reportable segment) and Diagnostic Solutions (DS, $250 million, 2.3%: ExamOne risk assessment for life insurers and healthcare IT such as Quanum).
- Scale: serves about one-third of US adults annually and about half of US physicians and hospitals; ~244 million test requisitions in 2025; ~2,400 patient service centers; >80 billion patient data points; nearly 57,000 employees (incl. ~6,800 at LifeLabs in Canada).
- Customer channels are physicians, hospitals (reference testing ~$1.2 billion; Collaborative Lab Solutions ~$800 million) and patients/consumers (QuestHealth.com, 150+ tests); Advanced Diagnostics generated over $1 billion on double-digit growth.
- Growth via outreach and lab acquisitions (target 1-2% revenue growth a year from M&A): Spectra Laboratories assets from Fresenius ($84 million), 51/49 lab JV with Corewell Health in Michigan; LifeLabs acquired in 2024.
- Efficiency: Invigorate targets 3% annual cost savings; Project Nova, an Epic-based modernization of "Order to Cash", runs to 2031-2032; AI collaboration with Google Cloud.
- Payer mix of DIS revenue: healthcare insurers 39%, client payers 31%, government 16%, patients 12%; capitated arrangements ~8% of revenue.
- Main risks: PAMA Medicare fee cuts (delayed repeatedly), payer utilization controls, OBBBA and expiry of ACA tax credits (up to 50-60 bp of revenue by 2028), competition from hospital labs and Laboratory Corporation of America, cybersecurity, labor supply.
- Capital return: dividend raised 7.5% to $0.86 per quarter in February 2026; additional $1 billion buyback authorized; ~$8.1 billion returned through buybacks since 2012.
- Quarterly Report on Form 10-Q for Q3 2026 (quarter ended September 30, 2026)
- Q3 2026 net revenues $3,097 million (+10.0%), DIS revenues $3,035 million (+10.2%, organic growth 10.1%), DS revenues $62 million.
- Nine months: net revenues $9,035 million (+9.8%, organic revenue growth 9.6%); operating income $1,337 million (+14.3%); net income attributable to Quest $884 million; diluted EPS $7.86 (+19.6%).
- Q3 DIS volume +14.5% (organic +14.4%), of which 9.5% came from the new Corewell Health Collaborative Lab Solutions relationship and higher testing at Fresenius Medical Care dialysis clinics; excluding them volume grew 5%.
- Revenue per requisition fell 4.2% because the Corewell/Fresenius work is mostly routine testing; excluding that mix it rose 1.7%, on more tests per requisition.
- Q3 operating income $479 million (15.5% margin vs 13.7%); diluted EPS $2.78 vs $2.16.
- The Corewell Health JV (51% Quest / 49% Corewell) closed in January 2026 and is consolidated; a new Michigan lab is due to be operational during 2027.
- Invigorate still targets 3% annual cost savings; Project Nova spend is adding to SG&A.
- Balance sheet: $500 million of 5.00% notes due 2036 issued in May 2026 to repay 3.45% notes; $250 million of buybacks in nine months; quarterly dividend $0.86; $1.2 billion of buyback authorisation left.
- Q3 2026 financial results press release (8-K Exhibit 99.1): raises 2026 guidance
- Q3 2026 revenues $3.10 billion, up 10.0%; reported diluted EPS $2.78 (+28.7%); adjusted diluted EPS $3.00 (+15.4%).
- Adjusted operating income $517 million, 16.7% of revenues (16.3% a year earlier).
- Full-year 2026 guidance raised: revenues $12.065-12.105 billion (+9.3% to 9.7%; prior $11.95-12.05 billion), reported EPS $10.21-10.31, adjusted EPS $11.25-11.35, operating cash flow about $1.90 billion, capex about $550 million.
- Jim Davis credits strength "across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI".
- Highlights: Apple Health app users will be able to buy a Quest panel of over 50 biomarkers; agreement to acquire outreach lab assets from a Northeastern US health system; AD-Detect panel with Roche pTau217; Project Nova moved to build phase with the first Epic lab deployment in fall 2027.
- Investor Day on March 25, 2027 at the NYSE; the release flags the cybersecurity incident disclosed in an 8-K the same day.
- Quest Diagnostics Q3 2026 earnings call transcript
- Q3 2026 revenues grew 10% and adjusted EPS over 15%; guidance raised to revenues of $12.065-12.105 billion and adjusted EPS of $11.25-11.35.
- Growth was broad: high single-digit revenue growth in physicians, double-digit growth in hospitals (driven by Co-Lab Solutions with Corewell Health), and consumer health growth expected to exceed 30% for the year.
- Volume excluding Corewell and Fresenius grew 5%; unit price "generally flat"; consumer margins are accretive (no denials, no patient concessions, dense requisitions).
- New consumer channel: an Apple Health app panel of over 50 biomarkers at "$119 rack", launching around year-end.
- Kidney care: Quest fielded a specialized sales force for nephrologists after taking on Fresenius dialysis testing.
- PAMA: 2027 impact estimated at about 1% of total revenues (under 1.3% cumulative for 2027-2029); Quest will offset part of it and lobbies for the RESULTS Act; Davis calls the CMS data collection "flawed".
- Automation and AI: automated aliquoting in 10 labs; AI scanning dialysis water samples at Clifton, NJ; Invigorate delivering 3% savings.
- A cybersecurity incident on a test-ordering system was disclosed the same day; management gave no further detail.
- Quest Diagnostics Q4 and full-year 2025 earnings call transcript
- 2025 delivered double-digit growth in revenues and EPS; Q4 revenues $2.81 billion (+7.1%, organic 6.4%), adjusted EPS $2.42.
- Initial 2026 guidance: revenues $11.7-11.82 billion (+6% to 7.1%), adjusted EPS $10.50-10.70, operating cash flow about $1.75 billion, capex about $550 million; no PAMA impact in 2026 after a one-year delay.
- Corewell Health: Co-Lab Solutions across all 21 Corewell hospitals, the largest to date, adding about $250 million of organic revenue at low single-digit margins in 2026; Co-Lab Solutions expected to generate about $1 billion of revenue in 2026.
- Fresenius Medical Care: Quest scaled testing to more than 200,000 patients at its US dialysis centers.
- Consumer channel: nearly $250 million of revenue in 2025; QuestHealth.com a $100 million run-rate business that grew about 35%; partners include WHOOP, Oura and Function Health; long-term target above 20% growth.
- Davis sees share gains against hospital outreach and physician office labs, helped by re-entering Elevance networks in several states and Sentara; Quest has over 1,200 sales reps.
- Innovation: AD-Detect Alzheimer's tests, ANAlyzer autoimmune, Haystack MRD and a new Flow MRD myeloma test; data business growing double digits.
- Project Nova costs about $0.25 of EPS in 2026; Davis pushes the RESULTS Act to fix PAMA.
Questions about Quest Diagnostics
What does Quest Diagnostics do?
Quest Diagnostics runs clinical laboratory testing for physicians, hospitals, payers and consumers in the United States, plus risk assessment for life insurers and healthcare IT.
What is Quest Diagnostics' revenue?
2025 net revenues were $11,035 million (+11.8%). 2026 guidance is $12.065-12.105 billion.
How many employees does Quest Diagnostics have?
Nearly 57,000, including ~6,800 at LifeLabs in Canada.
Who leads Quest Diagnostics?
Jim Davis is Chairman, CEO and President, and Sam Samad is CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)